Well as a small investor in AMRN , I would prefer they use say up to $100m of that cash on hand to fund small niche trials ...say post PCI patients ....without a mineral oil placebo .
If those results ...even after 2-3 yrs ( event line separation ) ...come anywhere near close to what was seen in US R-IT PCI ....then AMRN is worth a lot more than $2 a share .
The key would be to have the EU health depts ( where AMRN has exclusivity ) being willing to accept the results of a short term trial .